Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Epanutin

- PMLiVE

Pfizer’s PCSK9 inhibitor clears another phase III trial

Bococizumab will compete with Praluent and Repatha if it reaches the market

- PMLiVE

Japanese approvals for GSK, AZ and Bayer

MHLW gives Nucala, Tagrisso and Xofigo the green light

- PMLiVE

Med comms has a ‘big role to play’ in market access

HCA meeting hears communications can assist companies with the process

- PMLiVE

Norman Lamb: Health savings ‘unachievable’ under current approach

Former minister says health system's ‘existential challenge’ needs new thinking

- PMLiVE

3D printed epilepsy drug launched in the US

Aprecia’s Spritam is now available as a prescription drug

- PMLiVE

Britain facing social care ‘time bomb’

Raising awareness of financial realities is key first step, Astellas Debate hears

- PMLiVE

Positive trials bring Pfizer closer to new use for Xeljanz

Rheumatoid arthritis drug performs in two ulcerative colitis trials

- PMLiVE

FDA allows accelerated review for rivals to over-priced drugs

Aims to combat growing trend in exploitation of sole-source drug pricing

- PMLiVE

GW ascendant as epilepsy drug clears phase III trial

Epidiolex proves effective in controlling seizures in children with Dravet syndrome

- PMLiVE

How AbbVie Care is putting patients at the centre

And why this is good news for everyone

- PMLiVE

Pfizer gets FDA OK for expanded use of lung cancer drug Xalkori

First NSCLC treatment targeting the rare ROS1 mutation to be approved in the US

ABPI London offices

UK pharma’s contribution to NHS hits £1bn mark

ABPI says local access to new treatments still not universal despite drug rebates

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links